Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by LouisWon Mar 17, 2022 1:34am
167 Views
Post# 34520863

Neurotoxicity caused by docetaxel

Neurotoxicity caused by docetaxelI believe decetaxel was release from TH1902 inside SORT1 positive cells including cancerous cells and neuronal cells. Otherwise, TH cannot observe the similar effect which was also observed with higher docetaxel along. Refering to the feedback from Christian....

I personally dont know if cancerous cells express more SORT1 than neuronal cells but I hope cancerous cells were jeopardized lot more than the normal cells due to more SORT1 protein on cancer cell membrane.

Christian said....
Yeah, what we've seen is our adverse events are linked to when you get a higher dose of docetaxel. At some point you get [indiscernible] or go higher to a certain level. And what you see with docetaxel, they seem the same after two or three cycles. That's what the signs of neurotoxicity that's seen with those docetaxel. We've seen also some signs on visual acuity seen with docetaxel and some fatigue. 



<< Previous
Bullboard Posts
Next >>